Dosage forms having prolonged active ingredient release

Details Dosage forms having prolonged active ingredient release Dosage forms having prolonged active ingredient release

A - Human Necessities

61

K

A61K 9/22 (2006.01) A61K 9/20 (2006.01) A61K 9/32 (2006.01) A61K 31/192 (2006.01) A61K 9/28 (2006.01)

Patent

CA 2459165

A pharmaceutical unit dosage form comprising a therapeutically effective dose of a 4-phenylbutyric acid salt having prolonged release of the active ingredient, being suitable for alleviating and curing various diseases upon once or twice daily oral administration, a method of preparation of said pharmaceutical formulation and the use thereof for the treatment of benign prostate hyperplasy, cancer, leukemias, cystic fibrosis, AIDS, kidney and liver diseases, thalassemia and urea cycle disorders comprising the twice- daily oral administration of a therapeutically effective dosage thereof to a patient.

L'invention concerne une forme posologique comprenant une dose thérapeutiquement efficace d'un sel d'acide 4-phénylbutyrique à libération prolongée de principe actif, permettant de soulager et de traiter diverses maladies lorsqu'elle est administrée par voie orale une ou deux fois par jour. L'invention concerne également un procédé de préparation de cette formulation pharmaceutique et l'utilisation de celle-ci dans le traitement d'une hyperplasie bénigne de la prostate, d'un cancer, de leucémies, d'une fibrose kystique, du SIDA, de maladies des reins et du foie, d'une thalassémie et de troubles du cycle de l'urée par administration orale deux fois par jour d'un dosage thérapeutiquement efficace de la formulation à un patient.

Affiliated with

Also associated with

Rating

Dosage forms having prolonged active ingredient release does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dosage forms having prolonged active ingredient release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage forms having prolonged active ingredient release will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1728578